Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology
Clinical trials are expected to start in the second half of 2022
BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of $150 million, and will be eligible to receive future approval and sales milestone payments totaling up to $200 million as well as a share of gross profits arising from future product sales
Pfizer will receive an upfront payment of $25 million from BioNTech for its proprietary antigen sequences identified by Pfizer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.